1. Home
  2. BILL vs TARS Comparison

BILL vs TARS Comparison

Compare BILL & TARS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo BILL Holdings Inc.

BILL

BILL Holdings Inc.

SELL

Current Price

$45.42

Market Cap

3.2B

Sector

Technology

ML Signal

SELL

Logo Tarsus Pharmaceuticals Inc.

TARS

Tarsus Pharmaceuticals Inc.

SELL

Current Price

$68.89

Market Cap

3.6B

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
BILL
TARS
Founded
2006
2016
Country
United States
United States
Employees
N/A
N/A
Industry
EDP Services
Medicinal Chemicals and Botanical Products
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.2B
3.6B
IPO Year
2019
2020

Fundamental Metrics

Financial Performance
Metric
BILL
TARS
Price
$45.42
$68.89
Analyst Decision
Buy
Strong Buy
Analyst Count
22
10
Target Price
$57.00
★ $99.80
AVG Volume (30 Days)
★ 1.4M
589.3K
Earning Date
11-05-2026
11-03-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 48.21
EPS
★ N/A
N/A
Revenue
★ $1,653,160,000.00
$451,360,000.00
Revenue This Year
$10.70
$61.17
Revenue Next Year
$9.53
$26.47
P/E Ratio
★ N/A
N/A
Revenue Growth
13.03
★ 146.71
52 Week Low
$31.41
$53.89
52 Week High
$57.21
$91.53

Technical Indicators

Market Signals
Indicator
BILL
TARS
Relative Strength Index (RSI) 49.59 37.84
Support Level $41.01 $60.95
Resistance Level $46.60 $69.48
Average True Range (ATR) 1.47 2.92
MACD 0.29 -0.73
Stochastic Oscillator 64.12 2.44

Price Performance

Historical Comparison
BILL
TARS

About BILL BILL Holdings Inc.

BILL Holdings Inc is a provider of software-as-a-service, cloud-based payments and spend and expense management products, which allow users to automate accounts payable and accounts receivable transactions, enable businesses to easily connect with their suppliers or customers to do business, eliminate expense reports, manage cash flows and improve back office efficiency. Initial Public Offering and Follow-on Offering.

About TARS Tarsus Pharmaceuticals Inc.

Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis. TP-04 for the potential treatment of ocular rosacea and TP-05 for potential Lyme disease prophylaxis and community malaria reduction.

Share on Social Networks: